We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Jaime Llinares Taboada
Beximco Pharmaceuticals Ltd. said Monday that it has signed a contract for distribution of certain products of Mylan NV in Bangladesh.
The London-listed company said it will receive the exclusive rights to launch Mylan's portfolio of monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Crohn's disease, ulcerative colitis and other medical conditions.
The first product to be launched, in the first quarter of 2020, will be Ogivri, a breast-cancer drug which is biosimilar to blockbuster drug Herceptin from Roche Holding AG, Beximco said.
Shares at 0900 GMT were up 1.8 pence, or 4.2%, at 45.0 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
February 24, 2020 04:23 ET (09:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
